Under construction – not a live service
Sign in
Not yet taking people in United StatesPhase 4

Letermovir for R+ Study

Key facts

Who runs it
University of Wisconsin, Madison
Where
Madison, United StatesSee the site
Trial code
Status
Not yet recruiting
Phase
Phase 4
People taking part
146 people, planned
Started
Oct 2026
Expected to end
Sept 2029
Type of study
Interventional
Treatments tested
  • Letermovir
Record updated
29 September 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 5 criteriaShow less

Who can take part

  • Adults who are at moderate risk for CMV after transplant (CMV IGG+, including D+/R+ or D-/R+)
  • Adults who received a kidney transplant, liver transplant, or any combination thereof

Who cannot take part

  • Known contraindication to letermovir or its excipients
  • Current participation in another CMV related study
  • Unwilling or unable to participate in the study protocol

Where in United States

  • University of Wisconsin - MadisonMadison, United StatesContact: Office of Clinical Research Department of SurgeryNo longer taking part

About the trial

What the trial wants to find out

The purpose of this clinical trial is to find out whether a medication, called letermovir, can help prevent a virus called cytomegalovirus (CMV) in participants who receive a kidney or liver transplant and who have already been exposed the CMV.

Read full original descriptionShow less

Participants will take letermovir for 84 days.

The group in the trial

  • Receive letermovirTreatment being tested

    Participants will take letermovir

    Treatment: Letermovir

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
An Interventional Study of Letermovir for Primary Prophylaxis of Cytomegalovirus Infection in Moderate Risk (R+) Abdominal Solid Organ Transplant Recipients
Record updated
29 September 2026